KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Net Cash Flow (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of Net Cash Flow data on record, last reported at $188.2 million in Q4 2025.

  • For Q4 2025, Net Cash Flow fell 79.21% year-over-year to $188.2 million; the TTM value through Dec 2025 reached -$304.2 million, down 145.09%, while the annual FY2025 figure was -$304.2 million, 145.09% down from the prior year.
  • Net Cash Flow reached $188.2 million in Q4 2025 per SRPT's latest filing, up from $100.0 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $905.2 million in Q4 2024 and bottomed at -$882.0 million in Q1 2022.
  • Average Net Cash Flow over 5 years is -$34.9 million, with a median of -$32.2 million recorded in 2021.
  • Peak YoY movement for Net Cash Flow: surged 1714.55% in 2021, then tumbled 75526.58% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at $517.3 million in 2021, then plummeted by 113.89% to -$71.8 million in 2022, then plummeted by 62.95% to -$117.1 million in 2023, then soared by 873.16% to $905.2 million in 2024, then crashed by 79.21% to $188.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were $188.2 million in Q4 2025, $100.0 million in Q3 2025, and $269.7 million in Q2 2025.